Please assess the completion status of the following clinical trial:

Trial Title: Progesterone and Resting Energy Expenditure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women during early menopausal transition (MT) with indication for luteal phase progesterone substitution (definition of early MT: change of cycle length (shorter or longer menstrual cycle) of at least ≥ 7 days from normal and/or phases of amenorrhea of up to \< 60 days during the preceding 12 months)~* Body Mass Index (BMI) 18.5 - 24.9 kg/m2~* Informed Consent as documented by signature~Exclusion Criteria:~* Pregnancy or Lactation~* Systemic hormone therapy or hormonal contraception (estradiol, progestogen, androgen) during the study and within 12 weeks prior to study entry~* Phytotherapeutics for menstrual cycle regulation during the study and within 12 weeks prior to study entry~* Active psychiatric disease~* Use of psychotropic drugs during the study and within 12 weeks prior to study entry~* Nicotin abuse \> 10 cigarettes/day~* Alcohol abuse~* Use of appetite suppressants~* Diabetes mellitus~* Untreated Hypo- and hyperthyroidism~* Hypersensitivity to progesterone~* Hypersensitivity to sunflower oil, soy lecithin and other ingredients of Utrogestan® such as gelatine, glycerol, E171 (titanium dioxide)~* Contraindication of progesterone medication according to swissmedicinfo.ch (suspected or diagnosed neoplasia of the breast or other sexual organ; benign or malignant liver Tumors (also in medical history); acute or chronic liver disease (Rotor- or Dubin-Johnson-Syndrome); cholestatic jaundice; porphyria; arterial or venous thromboembolic Events and cerebral bleedings; abnormal genital bleeding of unknown cause)~* Use of barbiturates, antiepileptic drugs, tuberculostatic drugs, antiretroviral drugs, antimycotic drugs, antibiotic drugs, Hypericum perforatum and Spironolactone~* Known or suspected non-compliance, drug or alcohol abuse etc.~* Illiteracy~* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Utrogestan (Type: EXPERIMENTAL): 300mg Utrogestan (1 tablet 100mg + 1 tablet 200mg)by mouth,every day in the second and third menstrual cycle daily from cycle day 15 to 26.

Based on this trial design, predict the completion outcome and termination type (if applicable).